The aspirin cardiovascular/gastrointestinal risk calculator ‐ a tool to aid clinicians in practice

Summary Background Assessment of both GI and CV risks vs. the benefits of low‐dose aspirin for individual patients can be difficult in clinical practice. Aim To develop a tool to estimate CV and GI risks to facilitate the clinical decision‐making process. Methods We constructed risk‐ratio estimation...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Alimentary pharmacology & therapeutics 2013-04, Vol.37 (7), p.738-748
Hauptverfasser: Lanas, A., Polo‐Tomás, M., Casado‐Arroyo, R.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 748
container_issue 7
container_start_page 738
container_title Alimentary pharmacology & therapeutics
container_volume 37
creator Lanas, A.
Polo‐Tomás, M.
Casado‐Arroyo, R.
description Summary Background Assessment of both GI and CV risks vs. the benefits of low‐dose aspirin for individual patients can be difficult in clinical practice. Aim To develop a tool to estimate CV and GI risks to facilitate the clinical decision‐making process. Methods We constructed risk‐ratio estimations and determined the incidence of CV events and upper GI complications according to the presence of different risk factors. For upper GI complications we assumed a baseline incidence of 1 case/1000‐persons‐year, a twofold increased risk with low‐dose aspirin, and estimated a 60% GI risk reduction with proton pump inhibitors (PPI) co‐therapy and a 60% risk reduction with H. pylori eradication in patients with a history of peptic ulcer. Results The calculator can be found at http://www.asariskcalculator.com. In patients with low CV risk the number of GI complications induced by low‐dose aspirin may be greater than the number of CV events prevented. In patients with high CV risk, low‐dose aspirin is recommended, but the number of GI complications induced may still overcome the CV events saved. The use of PPI reduces the number of complication events induced by low‐dose aspirin, but the number of CV events saved may still be offset by the number of GI complications induced in patients at very high GI risk. Conclusions There are many clinical situations where the number of potential upper GI complications induced by low‐dose aspirin may exceed the number of potentially prevented CV events. A risk calculator should guide physicians in choosing appropriate therapy and maximise the aspirin benefit.
doi_str_mv 10.1111/apt.12240
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1314894102</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1314894102</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3900-56da56dd3cf746de044426bbb3d2affc5b0d3c30d4b738a21d96435d427f97193</originalsourceid><addsrcrecordid>eNp1kEtOwzAQhi0EoqWw4ALIGyRYpPUrSbOsKl5SJViUdTSxHTC4SbATUHccgTNyElxSYMVIHi_m0z-jD6FjSsY01ASadkwZE2QHDSlP4ogRnuyiIWFJFrEp5QN04P0TISRJCdtHA8YF5dlUDJFaPmoMvjHOVFiCU6Z-BS87C27yAL51tala7VtTgcXO-OcA2c24rR3-fP_AgNu6tqFhMApLayojDVQeh7zGgWyN1IdorwTr9dH2H6H7y4vl_Dpa3F7dzGeLSPKMkChOFISnuCxTkShNhBAsKYqCKwZlKeOChBknShQpnwKjKksEj5VgaZmlNOMjdNbnNq5-6cLV-cp4qa2FStedzymnYpoJSlhAz3tUutp7p8u8cWYFbp1Tkm-k5kFq_i01sCfb2K5YafVL_lgMwOkWCOrAlg4qafwfl1IRc77hJj33Zqxe_78xn90t-9VfZFKPVw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1314894102</pqid></control><display><type>article</type><title>The aspirin cardiovascular/gastrointestinal risk calculator ‐ a tool to aid clinicians in practice</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><creator>Lanas, A. ; Polo‐Tomás, M. ; Casado‐Arroyo, R.</creator><creatorcontrib>Lanas, A. ; Polo‐Tomás, M. ; Casado‐Arroyo, R.</creatorcontrib><description>Summary Background Assessment of both GI and CV risks vs. the benefits of low‐dose aspirin for individual patients can be difficult in clinical practice. Aim To develop a tool to estimate CV and GI risks to facilitate the clinical decision‐making process. Methods We constructed risk‐ratio estimations and determined the incidence of CV events and upper GI complications according to the presence of different risk factors. For upper GI complications we assumed a baseline incidence of 1 case/1000‐persons‐year, a twofold increased risk with low‐dose aspirin, and estimated a 60% GI risk reduction with proton pump inhibitors (PPI) co‐therapy and a 60% risk reduction with H. pylori eradication in patients with a history of peptic ulcer. Results The calculator can be found at http://www.asariskcalculator.com. In patients with low CV risk the number of GI complications induced by low‐dose aspirin may be greater than the number of CV events prevented. In patients with high CV risk, low‐dose aspirin is recommended, but the number of GI complications induced may still overcome the CV events saved. The use of PPI reduces the number of complication events induced by low‐dose aspirin, but the number of CV events saved may still be offset by the number of GI complications induced in patients at very high GI risk. Conclusions There are many clinical situations where the number of potential upper GI complications induced by low‐dose aspirin may exceed the number of potentially prevented CV events. A risk calculator should guide physicians in choosing appropriate therapy and maximise the aspirin benefit.</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1111/apt.12240</identifier><identifier>PMID: 23413984</identifier><language>eng</language><publisher>Oxford: Blackwell</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Algorithms ; Aspirin - administration &amp; dosage ; Aspirin - adverse effects ; Biological and medical sciences ; Cardiovascular Diseases - chemically induced ; Cardiovascular Diseases - prevention &amp; control ; Digestive system ; Dose-Response Relationship, Drug ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Gastrointestinal Hemorrhage - chemically induced ; Gastrointestinal Hemorrhage - prevention &amp; control ; Gastrointestinal Tract - drug effects ; Humans ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Platelet Aggregation Inhibitors - administration &amp; dosage ; Platelet Aggregation Inhibitors - adverse effects ; Proton Pump Inhibitors - administration &amp; dosage ; Risk Assessment - methods ; Risk Factors ; Young Adult</subject><ispartof>Alimentary pharmacology &amp; therapeutics, 2013-04, Vol.37 (7), p.738-748</ispartof><rights>2013 Blackwell Publishing Ltd</rights><rights>2014 INIST-CNRS</rights><rights>2013 Blackwell Publishing Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3900-56da56dd3cf746de044426bbb3d2affc5b0d3c30d4b738a21d96435d427f97193</citedby><cites>FETCH-LOGICAL-c3900-56da56dd3cf746de044426bbb3d2affc5b0d3c30d4b738a21d96435d427f97193</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fapt.12240$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fapt.12240$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=27145334$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23413984$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lanas, A.</creatorcontrib><creatorcontrib>Polo‐Tomás, M.</creatorcontrib><creatorcontrib>Casado‐Arroyo, R.</creatorcontrib><title>The aspirin cardiovascular/gastrointestinal risk calculator ‐ a tool to aid clinicians in practice</title><title>Alimentary pharmacology &amp; therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Summary Background Assessment of both GI and CV risks vs. the benefits of low‐dose aspirin for individual patients can be difficult in clinical practice. Aim To develop a tool to estimate CV and GI risks to facilitate the clinical decision‐making process. Methods We constructed risk‐ratio estimations and determined the incidence of CV events and upper GI complications according to the presence of different risk factors. For upper GI complications we assumed a baseline incidence of 1 case/1000‐persons‐year, a twofold increased risk with low‐dose aspirin, and estimated a 60% GI risk reduction with proton pump inhibitors (PPI) co‐therapy and a 60% risk reduction with H. pylori eradication in patients with a history of peptic ulcer. Results The calculator can be found at http://www.asariskcalculator.com. In patients with low CV risk the number of GI complications induced by low‐dose aspirin may be greater than the number of CV events prevented. In patients with high CV risk, low‐dose aspirin is recommended, but the number of GI complications induced may still overcome the CV events saved. The use of PPI reduces the number of complication events induced by low‐dose aspirin, but the number of CV events saved may still be offset by the number of GI complications induced in patients at very high GI risk. Conclusions There are many clinical situations where the number of potential upper GI complications induced by low‐dose aspirin may exceed the number of potentially prevented CV events. A risk calculator should guide physicians in choosing appropriate therapy and maximise the aspirin benefit.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Algorithms</subject><subject>Aspirin - administration &amp; dosage</subject><subject>Aspirin - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Cardiovascular Diseases - chemically induced</subject><subject>Cardiovascular Diseases - prevention &amp; control</subject><subject>Digestive system</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Gastrointestinal Hemorrhage - chemically induced</subject><subject>Gastrointestinal Hemorrhage - prevention &amp; control</subject><subject>Gastrointestinal Tract - drug effects</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Platelet Aggregation Inhibitors - administration &amp; dosage</subject><subject>Platelet Aggregation Inhibitors - adverse effects</subject><subject>Proton Pump Inhibitors - administration &amp; dosage</subject><subject>Risk Assessment - methods</subject><subject>Risk Factors</subject><subject>Young Adult</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kEtOwzAQhi0EoqWw4ALIGyRYpPUrSbOsKl5SJViUdTSxHTC4SbATUHccgTNyElxSYMVIHi_m0z-jD6FjSsY01ASadkwZE2QHDSlP4ogRnuyiIWFJFrEp5QN04P0TISRJCdtHA8YF5dlUDJFaPmoMvjHOVFiCU6Z-BS87C27yAL51tala7VtTgcXO-OcA2c24rR3-fP_AgNu6tqFhMApLayojDVQeh7zGgWyN1IdorwTr9dH2H6H7y4vl_Dpa3F7dzGeLSPKMkChOFISnuCxTkShNhBAsKYqCKwZlKeOChBknShQpnwKjKksEj5VgaZmlNOMjdNbnNq5-6cLV-cp4qa2FStedzymnYpoJSlhAz3tUutp7p8u8cWYFbp1Tkm-k5kFq_i01sCfb2K5YafVL_lgMwOkWCOrAlg4qafwfl1IRc77hJj33Zqxe_78xn90t-9VfZFKPVw</recordid><startdate>201304</startdate><enddate>201304</enddate><creator>Lanas, A.</creator><creator>Polo‐Tomás, M.</creator><creator>Casado‐Arroyo, R.</creator><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201304</creationdate><title>The aspirin cardiovascular/gastrointestinal risk calculator ‐ a tool to aid clinicians in practice</title><author>Lanas, A. ; Polo‐Tomás, M. ; Casado‐Arroyo, R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3900-56da56dd3cf746de044426bbb3d2affc5b0d3c30d4b738a21d96435d427f97193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Algorithms</topic><topic>Aspirin - administration &amp; dosage</topic><topic>Aspirin - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Cardiovascular Diseases - chemically induced</topic><topic>Cardiovascular Diseases - prevention &amp; control</topic><topic>Digestive system</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Gastrointestinal Hemorrhage - chemically induced</topic><topic>Gastrointestinal Hemorrhage - prevention &amp; control</topic><topic>Gastrointestinal Tract - drug effects</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Platelet Aggregation Inhibitors - administration &amp; dosage</topic><topic>Platelet Aggregation Inhibitors - adverse effects</topic><topic>Proton Pump Inhibitors - administration &amp; dosage</topic><topic>Risk Assessment - methods</topic><topic>Risk Factors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lanas, A.</creatorcontrib><creatorcontrib>Polo‐Tomás, M.</creatorcontrib><creatorcontrib>Casado‐Arroyo, R.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Alimentary pharmacology &amp; therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lanas, A.</au><au>Polo‐Tomás, M.</au><au>Casado‐Arroyo, R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The aspirin cardiovascular/gastrointestinal risk calculator ‐ a tool to aid clinicians in practice</atitle><jtitle>Alimentary pharmacology &amp; therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>2013-04</date><risdate>2013</risdate><volume>37</volume><issue>7</issue><spage>738</spage><epage>748</epage><pages>738-748</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>Summary Background Assessment of both GI and CV risks vs. the benefits of low‐dose aspirin for individual patients can be difficult in clinical practice. Aim To develop a tool to estimate CV and GI risks to facilitate the clinical decision‐making process. Methods We constructed risk‐ratio estimations and determined the incidence of CV events and upper GI complications according to the presence of different risk factors. For upper GI complications we assumed a baseline incidence of 1 case/1000‐persons‐year, a twofold increased risk with low‐dose aspirin, and estimated a 60% GI risk reduction with proton pump inhibitors (PPI) co‐therapy and a 60% risk reduction with H. pylori eradication in patients with a history of peptic ulcer. Results The calculator can be found at http://www.asariskcalculator.com. In patients with low CV risk the number of GI complications induced by low‐dose aspirin may be greater than the number of CV events prevented. In patients with high CV risk, low‐dose aspirin is recommended, but the number of GI complications induced may still overcome the CV events saved. The use of PPI reduces the number of complication events induced by low‐dose aspirin, but the number of CV events saved may still be offset by the number of GI complications induced in patients at very high GI risk. Conclusions There are many clinical situations where the number of potential upper GI complications induced by low‐dose aspirin may exceed the number of potentially prevented CV events. A risk calculator should guide physicians in choosing appropriate therapy and maximise the aspirin benefit.</abstract><cop>Oxford</cop><pub>Blackwell</pub><pmid>23413984</pmid><doi>10.1111/apt.12240</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0269-2813
ispartof Alimentary pharmacology & therapeutics, 2013-04, Vol.37 (7), p.738-748
issn 0269-2813
1365-2036
language eng
recordid cdi_proquest_miscellaneous_1314894102
source MEDLINE; Access via Wiley Online Library; EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection)
subjects Adolescent
Adult
Aged
Aged, 80 and over
Algorithms
Aspirin - administration & dosage
Aspirin - adverse effects
Biological and medical sciences
Cardiovascular Diseases - chemically induced
Cardiovascular Diseases - prevention & control
Digestive system
Dose-Response Relationship, Drug
Female
Gastroenterology. Liver. Pancreas. Abdomen
Gastrointestinal Hemorrhage - chemically induced
Gastrointestinal Hemorrhage - prevention & control
Gastrointestinal Tract - drug effects
Humans
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Platelet Aggregation Inhibitors - administration & dosage
Platelet Aggregation Inhibitors - adverse effects
Proton Pump Inhibitors - administration & dosage
Risk Assessment - methods
Risk Factors
Young Adult
title The aspirin cardiovascular/gastrointestinal risk calculator ‐ a tool to aid clinicians in practice
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T21%3A21%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20aspirin%20cardiovascular/gastrointestinal%20risk%20calculator%20%E2%80%90%20a%20tool%20to%20aid%20clinicians%20in%20practice&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=Lanas,%20A.&rft.date=2013-04&rft.volume=37&rft.issue=7&rft.spage=738&rft.epage=748&rft.pages=738-748&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1111/apt.12240&rft_dat=%3Cproquest_cross%3E1314894102%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1314894102&rft_id=info:pmid/23413984&rfr_iscdi=true